Condition
Chronic Urticaria, Idiopathic
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 4 (2)
Trial Status
Active Not Recruiting1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06555328Phase 2TerminatedPrimary
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
NCT05916937Phase 4Recruiting
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
NCT04774315Phase 4Active Not RecruitingPrimary
Molecular Endotypes of Chronic Idiopathic Urticaria
Showing all 3 trials